What is Ocular Hypertension Market Report?

it is all about ocular hypertension

What is Ocular Hypertension?

Ocular hypertension is defined as elevated intraocular pressure (IOP) without evidence of structural or functional damage by standard clinical tests. The patient with OHT must have open angles and no evidence of an ocular or systemic cause of the elevated IOP. Although genetic influences on IOP are being uncovered, genetic testing does not yet influence the diagnosis of OHT. Many different thresholds have been used to define OHT.

The increase in intraocular pressure (progressive with age, although it may also be due to other disorders or causes) is the main risk factor for developing glaucoma, and therefore, people with ocular hypertension are more likely to suffer the disease. However, the two are different: ocular hypertension means that the intraocular pressure is high, but the optic nerve is not damaged, whereas with glaucoma, the optic nerve has been damaged – and intraocular pressure might be normal or high – which can lead patients to notice a loss of visual field and even central vision in advanced stages of the disorder.

Prior to diagnosis, a thorough examination must be performed to rule out secondary causes of elevated IOP. Additional risk factors must be considered to estimate each patient’s probability of progression to glaucoma. The decision to initiate treatment should be based on the patient’s risk profile, as well as his or her age, medical status, life expectancy, and preferences. Patients need to be followed for changes such as disc hemorrhages, which suggest an increased risk of progression. Both treated and untreated patients should be followed for structural and functional damage suggestive of glaucoma. If these changes are seen, treatment should be initiated or accelerated.

What is Ocular Hypertension Diagnosis & Treatment?

The current mainstays for OHT treatment includes the use of symptomatic medical care to reduce the intraocular eye pressure followed by surgery in high risk individuals who do not demonstrate positive intraocular control with existing medical care. Topical therapies majorly comprise of beta-blockers, carbonic anhydrase inhibitors, prostaglandin derivatives, sympathomimetics, and miotics.

It covers the details of conventional and current medical therapies, and diagnosis available in the Ocular Hypertension market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States.

The DelveInsight Ocular Hypertension market report gives a thorough understanding of Ocular Hypertension symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides Ocular Hypertension symptoms of treatment algorithms and treatment guidelines for Ocular Hypertension symptoms in the United States.

What is Global Ocular Hypertension Market?

DelveInsight’s ‘Ocular Hypertension – Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the Ocular Hypertension, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, France, Italy, Spain and the United Kingdom), and Japan.

The Ocular Hypertension market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Ocular Hypertension symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current Ocular Hypertension symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market

What are the Ocular Hypertension Market Drugs Chapters?

The drug chapter segment of the Ocular Hypertension report encloses the detailed analysis of Ocular Hypertension marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Ocular Hypertension clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Prostaglandin analogs (PGAs) are recommended as the first-choice treatment for POAG because of their efficacy, limited systemic side effects, and once-daily dosing. These drugs reduce IOP by stimulating aqueous humor drainage, primarily through the uveoscleral outflow pathway. Latanoprost, bimatoprost, travoprost, and tafluprost, all PGF2a analogues, are currently approved for glaucoma therapy in the US and EU. Beta blockers, combination therapies, carbonic anhydrase inhibitors constitute second line of therapy for treatment of OHT.

What are the Ocular Hypertension Emerging Drugs?

NCX 470 is a novel, second-generation nitric oxide (NO)-donating prostaglandin analog which is currently being developed by Nicox Ophthalmics in Phase II multicenter, clinical study for the lowering of IOP in patients with OAG or OHT in the US.

What is Reimbursement Scenario in Ocular Hypertension?

While many individuals wait until their claim has been denied before seeking the services of a Social Security attorney, the patient should consider retaining legal representation before submitting the initial application. By working with an attorney or advocate, the patient will ensure that patient’s claim has sufficient supportive medical evidence and that it will be processed through the Compassionate Allowances program. An attorney will do his or her best to make sure that the patient receives Social Security Disability benefits as quickly as possible and will help the patient avoid the lengthy disability appeal process.

Comments are closed.